Showing 4391-4400 of 5646 results for "".
- Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edemahttps://modernod.com/news/adverum-provides-update-on-advm-022-and-the-infinity-trial-in-patients-with-diabetic-macular-edema/2479404/Adverum Biotechnologies provided an update on the ADVM-022 development program following a thorough review of data available from the INFINITY clinical trial in patients with diabetic macular edema (DME) and the OPTIC clinical trial in patients with wet age-related macular degeneration (AMD). The
- Johnson & Johnson Vision Launches Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-introduces-veritas-vision-system-with-features-to-address-key-unmet-needs-in-cataract-surgery/2479401/Johnson & Johnson Vision announced the global availability of the Veritas Vision System, a next-generation phacoemulsification system designed to address three critical areas: patient safety, surgeon efficiency and comfort. The company will offer live demos of the new system in a wet lab at t
- Ocuphire Announces Publication Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Diseasehttps://modernod.com/news/ocuphire-announces-publication-featuring-its-oral-ref-1-inhibitor-apx3330-in-phase-2-trial-for-the-treatment-of-retinal-disease/2479396/Ocuphire Pharma announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease. The article is titled “APE1/Ref-1 as a Novel Target for Retinal Disease.” The Journal of Cellula
- Monty Montoya Appointed CEO of TherOptixhttps://modernod.com/news/monty-montoya-appointed-ceo-of-theroptix/2479395/Monty Montoya has been named chief executive officer of TherOptix, a preclinical biopharma company focused on delivering clinically impactful therapeutics via a drug-eluting contact lens platform. TherOptix has received orphan drug designation on its lead candidate (001) for prevention of prolife
- Alcon to Share New Data and Live Booth Presentations at ASCRShttps://modernod.com/news/alcon-to-share-new-data-and-live-booth-presentations-at-ascrs/2479391/Alcon will have approximately 70 abstracts highlighting the benefits of the Alcon Cataract and Refractive suite. A few highlights of the Alcon data include: Robust data demonstrates extremely high level of patient satisfaction and increased spectacle independence for market-leading <
- Iveric Bio Appoints Christopher Simms as Chief Commercial Officerhttps://modernod.com/news/iveric-bio-appoints-christopher-simms-as-chief-commercial-officer/2479390/Iveric bio announced the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he managed commercial operations for the U.S. Ophthalmics Franchise, launching Beovu (brolucizumab inje
- Euclid Systems Appoints Vance Thompson, MD, as Chief Medical Officerhttps://modernod.com/news/euclid-systems-appoints-vance-thompson-md-as-chief-medical-officer/2479383/Euclid Systems announced that it has appointed Vance Thompson, MD, an internationally recognized authority in laser vision correction and advanced cataract surgery, to the position of Chief Medical Officer. As an international researcher, Dr. Thompson has played a key role in the development of a
- Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at ASCRShttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-alg-1007-ex-u-s-phase-2-clinical-trial-for-dry-eye-disease-at-ascrs/2479379/Allegro Ophthalmics announced that the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry eye disease (DED) will be presented during the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) an
- iSTAR Medical Receives FDA Approval to Begin Trial for MINIject for Patients With Glaucomahttps://modernod.com/news/istar-medical-receives-fda-approval-to-begin-trial-for-miniject-for-patients-with-glaucoma/2479375/iSTAR Medical announced that the FDA granted it investigational device exemption (IDE) to start a trial with MINIject. The STAR-V study will investigate MINIject in over 350 patients with primary open-angle glaucoma. Glaucoma surgeons in the United States, Canada, and Europe will join the trial.<
- Heru Bolsters Executive Team with Seasoned Industry Veteranshttps://modernod.com/news/heru-bolsters-executive-team-with-seasoned-industry-veterans/2479373/Heru, a developer of wearable AI-powered vision diagnostics and augmentation software, has expanded its executive leadership team with the appointment of several strategic hires. Joining Heru are Mary Durbin, PhD, as Chief Scientific Officer; Bob George as Chief Technology Officer; Corey Nielson